Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Q1 2024 Earnings Presentation
24 slides from Cantargia Ab's earnings presentation, May 21, 2024
Slide 1: Q1 Report May 21, 2024
(oantargia Q1 REPORT May 21, 2024
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Significant events
Significant events… … in Quarter 1: • The first results from the ongoing clinical phase 1 study of CAN10 show that the antibody binds to the target IL1RAP and shows good safety. The study is progressing according to plan. • New clinical and preclinical results show that nadunolimab can reduce neurop
Slide 4: I. Project Status
I. PROJECT STATUS
Slide 5: Current pipeline
Current pipeline Project Disease Type of Discovery Preclinical — Clinical Clinical Clinical ' treatment phase phase phase | phase II phase Ill PDAC 1% line Gemcitabine/nab-paclitaxel Nadunolimab TNBC 15*/2"4 jine Carboplatin/gemcitabine NSCLC/ ' non-squamous NSCLC ine Platinum doublets Systeme se TT
Slide 6: Cantargia in 2024/25
Cantargia in 2024/25 • Data from the two clinical programs • Several clinical milestones during 2024 and 2025 • Publications and conference presentations • Nadunolimab: Presentations at both AACR and ASCO • CAN10: Three publications in impactful journals and presentation at one conference INCREASED
Slide 7: CAN10
CAN10
Slide 8: CAN10 - Targeting IL-1 family in inflammation
CAN10 - Targeting IL-1 family in inflammation • Evidence of IL-1 family cytokines (IL-1, IL-33, IL-36) driving inflammatory diseases • These cytokines are commonly upregulated and operate together in several diseases • Blockade of individual IL-1 family members insufficient • IL-1 and IL-36 targeti
Slide 9: CAN10 developed to block IL-1 family with precision
CAN10 developed to block IL-1 family with precision • CAN10 prevents signaling from IL1/, IL-33 and IL36// • CAN10 binds IL1RAP with pM affinity and prevents IL1RAP interaction with the IL-1, IL-33 and IL-36 receptors • CAN10 has shown robust efficacy in preclinical models of several diseases •
Slide 10: CAN10 first-in-human study ongoing
CAN10 first-in-human study ongoing Rational for psoriasis in MAD • IV administration in healthy volunteers (SAD) • Ongoing, receptor occupancy documented • No safety signals • SC administration in subjects with mild to moderate plaque psoriasis (MAD) • Strong rational for IL1RAP blockade in psoriasi
Slide 11: IL-1, IL-33 and IL-36 promote fibrosis in SSc fibroblasts
IL-1, IL-33 and IL-36 directly promotes fibrosis in SSc fibroblasts which can be counteracted by CAN10 Isotype CAN10 Collagen I SMA Collagen I staining ✱ ✱✱✱✱ ✱✱✱✱ ✱ ✱✱ 1.6 ### #### 2.0 ✱✱ #### # ## #### Fold changes #### Fold changes 1.5 1.2 1.0 0.8 0.5 0.4 0.0 0.0 DPBS TGF ILs$ ILs$ DPBS TGF IL
Slide 12: Systemic sclerosis: mCAN10 inhibits bleomycin-induced skin fibrosis
Systemic sclerosis: mCAN10 inhibits bleomycin- induced skin fibrosis Bleomycin (BLM) model mCAN10 10 mg/kg twice W BLM 2.5 mg/kg (daily s.c.) Nintedanib 50 mg/kg QD C57BL/6 Established fibrosis Termination n=10 per group Week 3 Week 6 No BLM (6 wks) Baseline BLM (3 wks) Dermal thickness Myofibroblas
Slide 13: Nadunolimab
NADUNOLIMAB
Slide 14: Nadunolimab and alleviation of neuropathy
Nadunolimab and alleviation of neuropathy → Chemotherapy induce neuropathy by several pathways including IL-1 (neuroinflammation) → Nadunolimab, phase 2 data in PDAC with Gem/nabP → lower Grade 3-4 peripheral neuropathy than expected from historical controls (1% vs 17%). → Further analysis from this
Slide 15: PDAC – Positive interim data in 1st line patients
PDAC – Positive interim data in 1st line patients OS and iPFS for mITT patients Best responses according to iRECIST 50% Best change in tumor size 0% -50% -100% iCPD iUPD iSD iPR Nadunolimab combination with Gem/Abraxane in 1st line PDAC (n=73): → 33% response rate with long OS and iPFS → Additional
Slide 16: 1st line PDAC – Strong efficacy in patients with high tumor IL1RAP
1st line PDAC – Strong efficacy in patients with high tumor IL1RAP level OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients (1st line, combination with Gem/Abraxane): →
Slide 17: TNBC – Promising early safety and efficacy
TNBC – Promising early safety and efficacy (1st/2nd line) Nadunolimab combination with Gem/Carbo in 1st/2nd line metastatic Best responses according to RECIST OS and PFS TNBC: 100% Best change in tumor size 15 patients enrolled in the dose- 50% escalation phase: → Preliminary ORR: 60% 0% (1 CR, 8 PR
Slide 18: Nadunolimab in 2024/25
Nadunolimab in 2024/25 • One randomized phase 2 clinical trial ongoing in TNBC • Two clinical trials to start (PDAC and AML/MDS) • A large number of precinical, translational and clinical results being analyzed • New data at ASCO 2024. SEVERALUPCOMING VALUE INFLECTION POINTS FOR NADUNOLIMAB 18
Slide 19: Cantargia IP
Cantargia IP → Lead candidate anti-IL1RAP antibody CAN04 Expiry year 2035 Granted (e.g. Europe, USA, China, Japan) Mother patent and divisionals → Lead candidate anti-IL1RAP antibody CAN10 Expiry year 2041 Granted (USA) Examination at early stage in remaining territories → Anti-IL1RAP for treatment
Slide 20: II. Finance
II. FINANCE
Slide 21: Financial highlights
Financial highlights Operating Expenses 78 5 -46% • Operating expenses decreased year over year by 46% to 42 (78) MSEK. 42 • R&D expenses amounted to 38 (73) MSEK. According to plan and due MSEK 3 to only two clinical trials (TRIFOUR and CAN10 phase 1) actively 73 recruiting, as well as no major inv
Slide 22: Available funds
Available funds MSEK 353 287 155 159 200 195 143 120 140 • Available funds decreased by 52 MSEK in the 197 108 quarter, from 195 to 143 (353) MSEK. 128 80 • The current available funds enable a runway of 12 55 35 months. 2023-03-31 2023-06-30 2023-09-30 2023-12-31 2024-03-31 Cash and bank balances S
Slide 23: II. News Flow and Q&A
II. NEWS FLOW AND Q&A
Slide 24: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC TNBC AML/MDS CAN10 milestones • Presentation at ASCO • Full recruitment H2 •Start phase I/II mid • Phase I data updates • NSCLC – Efficacy & on neuropathy 2024 2024 (DOD sponsored during 2024 (including biomarker data from • Start of Phase IIb trial •R